BioStock: Elicera Therapeutics enters agreement with BioNTech
Elicera Therapeutics’ push to develop novel immuno-oncology therapies just received a significant boost. The company has entered into a collaboration with the German contract development and manufacturing organisation BioNTech for the development of viral vectors to be used in Elicera’s ELC-401 project. Elicera expects to initiate a phase I/II trial with the CAR T-cell candidate in glioblastoma multiforme patients during the second half of 2023.
Read the article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se